Bukwang Pharmaceutical: Hepatitis B trials
The registry lists 19 Hepatitis B studies with Bukwang Pharmaceutical as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 2 3Phase 3 4Phase 4 10No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV PatientsTerminatedNCT01266005Phase 4
- A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)CompletedNCT01264367Phase 4
- An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis BCompletedNCT01264354Phase 4
- A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis BTerminatedNCT01264133Phase 4
- An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received ClevudineCompletedNCT01264107
- A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long PeriodTerminatedNCT01264094Phase 4
- A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCCCompletedNCT01263002Phase 4
- A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver FunctionCompletedNCT00641082Phase 4
- Long-term Study With ClevudineCompletedNCT00558818Phase 4
- Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B PatientsCompletedNCT00558493Phase 4
- Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBVCompletedNCT00501124Phase 4
- Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201TerminatedNCT00362700Phase 2
- Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 TrialCompletedNCT00362674
- Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB InfectionCompletedNCT00362635Phase 3
- Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 TrialsTerminatedNCT00362505Phase 3
- Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBVTerminatedNCT00313287Phase 3
- Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBVTerminatedNCT00313274Phase 3
- Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo GroupTerminatedNCT00313261Phase 2
- Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B VirusTerminatedNCT00305019Phase 2